Startup entity

BioFlorida

Company

market-trends is the sole category represented across all 1 tracked stories. Courtney Miller is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 5 runs below the beat's 6.3 for that window.

Last mentioned: Mar 10, 2026

Entity pulse

Recent coverage · BioFlorida

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about BioFlorida

market-trends is the sole category represented across all 1 tracked stories. Courtney Miller is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 5 runs below the beat's 6.3 for that window. Source depth averages 2 original sources per story, versus 2.3 across the same-window beat baseline. BioFlorida appears in 1 tracked Startup story from March 10, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 34 Startup stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering BioFlorida. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Clinical Milestones

    Anticipated updates on Phase 1/2 glioblastoma trial progress.

  2. BioFlorida Showcase

    Cornerstone Session presentation on Innovation in South Florida.

  3. Investival Showcase

    Presentation at the South Florida Rising Life Science Hub event.

  4. National Engagement

    Presented at BioCom California and BIO Investor Forum to engage global partners.

Stories mentioning BioFlorida 1

Market Trends Neutral

Myosin Therapeutics Showcases First-in-Class Glioblastoma Therapy in Florida

Myosin Therapeutics has been selected to present its novel nanomotor-dependency platform at two major South Florida life sciences conferences this March. The company is advancing MT-125, a first-in-class inhibitor currently in Phase 1/2 trials for glioblastoma, as it seeks to capitalize on South Florida's emergence as a biotechnology hub.

2 sources

BioFlorida is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.